NEW YORK, NY / ACCESS Newswire / February 7, 2025 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn about a potential recovery under the federal securities ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In AstraZenecaTo Contact Him Directly To Discuss Their Options If ...

NEW YORK, NY / ACCESS Newswire / February 6, 2025 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn about a potential recovery under the federal securities ...

AstraZeneca reports mixed results in the fourth quarter. It gains in pre-market after assuring investors that the business impact of the Chinese investigations remains minor.

AstraZeneca PLC (NASDAQ:AZN ) Q4 2024 Earnings Conference Call February 6, 2025 6:00 AM ET Company Participants Pascal Soriot – Executive Director and Chief Executive Officer Iskra Reic – Executive...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

AstraZeneca PLC (LSE:AZN) could face a fine of up to £4.5 million as the Chinese authorities investigate allegedly illegal imports of cancer drugs Imfinzi and Imjudo. The Shenzhen City Customs susp...

AstraZeneca PLC (LSE:AZN) shares climbed 3.5% in early trading, adding £6 billion to its market value, after reporting strong annual profits driven by its cancer, lung, and immunology treatments. R...

AstraZeneca forecast its 2025 sales above analysts' expectations on Thursday, after the drugmaker's fourth-quarter revenue beat estimates, driven by robust demand, especially for its medicines for ...

NEW YORK, NY / ACCESS Newswire / February 5, 2025 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn about a potential recovery under the federal securities ...

AstraZeneca investors will look past another strong set of quarterly results on Thursday to focus on the main issue overhanging shares: an investigation of a top executive by authorities in China, ...

NEW YORK, NY / ACCESS Newswire / February 4, 2025 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn about a potential recovery under the federal securities ...

The CHMP recommends approval for JNJ's subcutaneous formulation of Rybrevant in NSCLC and AstraZeneca's Imfinzi in limited-stage small-cell lung cancer.

NEW YORK , Feb. 4, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ: AZN) of a class action securities lawsuit. CLASS DEFINI...

SAN DIEGO , Feb. 4, 2025 /PRNewswire/ -- Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired AstraZeneca PLC (NASD...